Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 10-21

  Stimmel, Glen L ^a   Dopheide, Julie A ^a   Stahl, Stephen M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; MIRTAZAPINE; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR;

ALPHA ADRENERGIC RECEPTOR BLOCKING; APPETITE DISORDER; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GRAND MAL SEIZURE; HUMAN; INSOMNIA; RECEPTOR AFFINITY; REVIEW; SEDATION; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; MIANSERIN; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS;

EID: 0031029632     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. deBoer T, Maura G, Raiteri M, deVos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
2. Sambunaris A, Hesselink JK, Stahl SM. Development of new antidepressants. J Clin Psychiatry 1997 In press.
3. Potter WZ. Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996;57(suppl 4):4-8.
4. Haddjeri N, Blier P, deMontigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10(suppl 4):11-17.
5. deBoer T, Ruigt GSF, Berendsen HHG. The alpha-2 selective adrenoceptor antagonist Org 3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol 1995;10:S107-18.
6. deBoer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10(suppl 4):19-23.
7. deBoer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25.
8. Stimmel GL. Mood disorders. In: Herfindal ET, Gourley DR, eds. Textbook of therapeutics, 6th ed. Baltimore: Williams & Wilkins, 1996:1095-1116.
9. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
10. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995;29:387-95.
11. Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994;11:133-41.
12. Dopheide JA, Stimmel GL, Yi DD. Focus on nefazodone: a serotonergic drug for major depression. Hosp Formulary 1995;30:205-12.
13. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(2, suppl):34-44.
14. Leonard BE. Sub-types of serotonin receptors: biochemical changes and pharmacological consequences. Int Clin Psychopharmacol 1992;7:13-21.
15. Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. New York: Cambridge University Press, 1996:139-61.
16. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron tablets after single and multiple oral dosing. Hum Psychopharmacol 1995;10:S83-96.
17. Timmer CJ, Lohmann AAM, Huisman JAM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Data on file. Organon, Inc., West Orange, NJ.
18. Verhoeven CHJ, Vos RME, Bogaards JJP. Characterization and inhibition of human cytochrome P450 enzymes involved in the in vitro metabolism of mirtazapine. Presented at the International Symposium on Microsomes and Drug Oxidations, Los Angeles, CA, July 21-24, 1996.
19. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron tablets. Hum Psychopharmacol 1995;10:S97-106.
20. Organon, Inc. Data on file. West Orange, NJ; 1996.
21. Timmer CJ, Paanakker JE, Van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Data on file. Organon, Inc., West Orange, NJ.
22. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry 1985;46:276-7.
23. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990;19:241-55.
24. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6(suppl 2):11-21.
25. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50: 222-39.
26. Murdoch DL, Ashgar J, Ankier SI, McLaughlin A, Groenhout C, McInnes GT. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects [abstr 76P]. In: Proceedings of the British Pharmacological Society 1992:1920.
27. Anonymous. FDC reports. Pink Sheet. October 23, 1995:16-17.
28. Bremmer JD. A double-blind comparison of Org3770, amitriptyline and placebo in major depression. J Clin Psychiatry 1995;56:519-25.
29. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-71.
30. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-6.
31. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:S125-33.
32. Khan MC. A randomised, double-blind, placebo-controlled 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995;10:S119-24.
33. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145-50.
34. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-71.
35. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9.
36. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
37. Mullin J, Lodge A, Bennie E, McCreadie R, Bhatt GS, Fenton G. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol 1996;10:235-40.
38. Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996;93: 184-90.
39. Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995;5:441-6.
40. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995; 10(suppl 4):25-35.
41. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol 1995;10: S135-45.
42. American Psychiatric Association. Practice guideline for major depression in adults. Am J Psychiatry 1993;150(4,suppl):1-26.
43. Bremner JD, Smith WT. ORG 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur J Psychiatry 1996;10:5-15.
44. Preskorn S. Double-blind crossover study of mirtazapine, amitriptyline and placebo in patients with major depression. Presented at the annual meeting of the American Psychiatric Association, Washington DC, May 1996.
45. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Drug Invest 1994;8: 339-44.
46. Sorensen M, Jorgensen J, Viby-Mogensen J, Bettum V, Dunbar GC, Steffensen K. A double-blind group comparative study using the new antidepressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery. Acta Psychiatr Scand 1985;71:339-46.
47. Ruigt GSF, Kemp B, Groenhout CM, Kamphuisen HAC. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-4.
48. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45.
49. Sitsen JMA, Zivkov M. Mirtazapine-clinical profile. CNS Drugs 1995;4(suppl 1):39-48.
50. Mattila M, Mattila MJ, Vrijmoed-de Vries M, Kuitunen T. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 1989;65:81-8.
51. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
52. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8.
53. Nemeroff CB, De Vane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
54. Hoes MJAJM, Zeijpveld JHB. First report of mirtazapine overdose. Int J Psychopharmacol 1996;11:147.
55. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991;48:1027-33.
56. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988;8:347-9.
57. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991;52:108-11.
58. Stimmel GL. How to counsel patients about depression and its treatment. Pharmacotherapy 1995;15(Pt 2):100S-4.
59. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
60. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995;56:556-67.